Literature DB >> 9404762

Elevated levels of soluble adhesion molecules in serum of patients with diffuse panbronchiolitis.

H Mukae1, J Kadota, J Ashitani, H Taniguchi, H Mashimoto, S Kohno, S Matsukura.   

Abstract

STUDY
OBJECTIVE: Adhesion molecules have been implicated in the pathogenesis of inflammatory diseases. This study was designed to determine whether soluble adhesion molecules in serum reflect the disease activity in diffuse panbronchiolitis (DPB). PATIENTS AND METHODS: Using an enzyme-linked immunosorbent assay, we measured the serum levels of soluble L-, E-, and P-selectin (sL-, sE-, and sP-selectin), intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in 27 patients with DPB, 13 with bronchiectasis, and 15 normal adults. BAL was also performed, and the levels of interleukin (IL)-8 and IL-1 beta in BAL fluid (BALF) were measured.
RESULTS: The serum levels of these molecules were significantly elevated in DPB patients compared with the control subjects. DPB patients also had significant high levels of circulating sE- and sP-selectin compared with patients with bronchiectasis. There was a significant correlation between serum sE-selectin and the percentage of neutrophils in BALF in all patients. There was a significant inverse correlation between serum sE-selectin and percent vital capacity in DPB patients. In the same patients, the relationships between serum sE-selectin and BALF concentrations of IL-1 beta as well as between serum sL-selectin and BALF IL-8 were also significant. Treatment of DPB patients with macrolides significantly reduced the serum levels of these soluble adhesion molecules and BALF concentrations of IL-1 beta and IL-8.
CONCLUSIONS: Our results suggest that these soluble adhesion molecules, particularly selectins, may reflect the disease activity of DPB, and that their levels may be regulated by cytokines produced in the lungs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9404762     DOI: 10.1378/chest.112.6.1615

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

Review 1.  The anti-inflammatory effects of macrolides.

Authors:  D Wales; M Woodhead
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Macrolides in the respiratory tract in cystic fibrosis.

Authors:  Adam Jaffé; Mark Rosenthal
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

Review 3.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

4.  Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

Authors:  J Wolter; S Seeney; S Bell; S Bowler; P Masel; J McCormack
Journal:  Thorax       Date:  2002-03       Impact factor: 9.139

5.  Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells.

Authors:  K Sugiyama; R Shirai; H Mukae; H Ishimoto; T Nagata; N Sakamoto; H Ishii; S Nakayama; K Yanagihara; Y Mizuta; S Kohno
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

6.  Increased concentrations of human beta-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis.

Authors:  T Hiratsuka; H Mukae; H Iiboshi; J Ashitani; K Nabeshima; T Minematsu; N Chino; T Ihi; S Kohno; M Nakazato
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

7.  Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model.

Authors:  Towako Nagata; Hiroshi Mukae; Junichi Kadota; Tomayoshi Hayashi; Takeshi Fujii; Misuzu Kuroki; Ryo Shirai; Katsunori Yanagihara; Kazunori Tomono; Takehiko Koji; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.